Table 2.
Cost-Effectiveness of Cholinesterase Inhibitors and Memantine Among Age and Sex Subgroups
| Male | Female | Age 74 | |||||||
| Intervention | QALYs | Cost, $ | NMB, $ a | QALYs | Cost, $ | NMB, $a | QALYs | Cost, $ | NMB, $ a |
| Best supportive care | 0.747 | 37,992 | 74,058 | 0.759 | 38,731 | 75,119 | 0.726 | 36,560 | 72,340 |
| Rivastigmine oral monotherapy | 0.866 | 57,400 | 72,500 | 0.882 | 58,750 | 73,550 | 0.834 | 54,702 | 70,398 |
| Galantamine monotherapy | 0.896 | 59,596 | 74,804 | 0.915 | 61,437 | 75,813 | 0.859 | 55,774 | 73,076 |
| Galantamine-memantine | 0.953 | 37,020 | 105,930 | 0.965 | 37,505 | 107,245 | 0.932 | 36,138 | 103,662 |
| Memantine monotherapy | 1.279 | 48,138 | 143,712 | 1.302 | 49,046 | 146,254 | 1.235 | 46,386 | 138,864 |
| Donepezil monotherapy | 1.584 | 47,389 | 190,211 | 1.622 | 48,600 | 194,700 | 1.507 | 44,940 | 181,110 |
| Donepezil-memantine | 1.763 | 71,999 | 192,451 | 1.813 | 74,190 | 197,760 | 1.662 | 67,458 | 181,842 |
| Rivastigmine-memantine | 1.798 | 88,092 | 181,608 | 1.849 | 90,770 | 186,580 | 1.693 | 82,541 | 171,409 |
| Rivastigmine transdermal patch | 2.198 | 105,341 | 224,359 | 2.278 | 109,486 | 232,214 | 2.027 | 96,440 | 207,610 |
QALY, quality-adjusted life-years; ICER, Incremental cost-effectiveness ratio (expressed in 2020 US dollars per QALY); NMB, Net monetary benefit. aNet monetary benefit at willingness-to-pay threshold of $150,000/QALY. Treatments with the greatest net monetary benefits are highlighted in bold.